Biomarkers of miR-34 activity

A technology of biomarkers and markers, applied in the field of cancer therapy, can solve problems such as no effect and little effect

Inactive Publication Date: 2016-04-06
MIRNA THERAPEUTICS
View PDF16 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Thus, although there have been significant advances in the use of microRNAs in the diagnosis and treatment of a variety of cancers, specific microRNA therapies may be ineffective or less effective in certain subpopulations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers of miR-34 activity
  • Biomarkers of miR-34 activity
  • Biomarkers of miR-34 activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0118] Example 1 - Materials and methods

[0119] Cell culture, oligonucleotides and proliferation assays. Syngeneic cancer cells derived from MCF10A breast cancer and SW48, HCT116, DLD-1 and RKO colorectal cancer cell lines were obtained from Horizon Discovery Ltd (Cambridge, UK). See Table 3. Synthetic miRNA mimics and siRNA were purchased from Life Technologies (Ambion, Austin, TX). To stimulate the TP53 pathway, cells were pretreated with 10 μM etoposide for 28 h, and RNA was harvested for qRT-PCR analysis. Determine the use of each cell line using siRNA against EG5, a spindle protein required for proliferation 2000 (Invitrogen) or RNAiMAX TM (Invitrogen) for optimal transfection conditions. Reverse transfections were performed in duplicate or triplicate. In short, to contain 20 μl per well of 2000 (SW48, MCF10A, DLD-1, HCT116) or RNAiMAX (RKO) Add 5 μl of a solution of oligonucleotides in RNase-free water. The mixture was incubated at room temperature for 20 m...

Embodiment 3

[0138] Example 3 - miR-34a but not miR-215 induces TP53-regulated genes in the absence of TP53

[0139] To understand the miR-34-induced phenotype in TP53-positive and TP53-deficient cells, the expression levels of genes related to the TP53 / miR-34 axis were determined. A possible explanation for the TP53-independent effect is that these cells do not express endogenous SIRT1 or MDM4. However, as demonstrated by qRT-PCR, TP53 + / + and TP53 - / - The cells both carried detectable levels of SIRT1 and MDM4 mRNA, suggesting that the TP53-independent phenotype was not due to the absence of these gene products (Figure 8). In contrast, both mRNAs were reduced in cells transfected with miR-34, according to experimental data showing that SIRT1 and MDM4 are directly targeted by this miRNA (Yamakuchi et al., Proc Natl Acad Sci USA 105(36):13421-6 (2008); Mandke et al., PLoS One7(8):e42034 (2012)). Similarly, the miR-34a target MET and the miR-215 target BCL2 were specifically downregulate...

Embodiment 4

[0140] Example 4 - HDAC1 is a direct target of miR-34a

[0141] p21 CIP1 / WAF1 A plausible explanation for the TP53-independent upregulation is the potential involvement of other TP53 family members TP63 and TP73. These two proteins exert distinct roles from TP53; however, they also control a set of genes that overlap with those of TP53. Endogenous mRNA levels of TP63 and TP73 were determined in TP53 wild-type and TP53-deficient cells that had been transfected with miR-34a. However, none of these cells showed detectable levels of TP63 or TP73, suggesting the involvement of these gene products is unlikely (data not shown).

[0142] Next, the regulatory mechanism independent of TP53 and the controllable p21 CIP1 / WAF1 A nuclear regulator of expression. One candidate of interest is HDAC1 because it has a putative miR-34a binding site in its 3'UTR ( Figure 10 ), down-regulated in cells transfected with miR-34a ( Figure 11 ), and has been associated with p21 in the absence of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention is based in part on the discovery that miR-34 is independent of p53. It has been discovered that miR-34 functions in a TP53 -independent tumor suppression pathway. Specifically, miR-34-induced inhibition of cancer cell growth was found to be the same in p53-normal and p53-deficient cells. Thus, miR-34 has a more central role during tumor suppression that is uncoupled from p53. In the absence of p53, miR-34, unlike certain other miRNAs, is sufficient to induce an up-regulation of genes known to be regulated by p53, including but not limited to p21<CIP1 / WAF1>(CDKN1A), PUMA, BAX, NOXA, PHLDA3, and MDM2 and a down-regulation of HDAC1. Therefore, these biomarkers can be used as biomarkers of miR-34 activity. The invention is further based on the discovery that some of these biomarkers are indispensable for a therapeutic response to miR-34 activity, and are thus prerequisite biomarkers of miR-34 activity.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority of USSN 61 / 838,847, filed June 24, 2013, and USSN 61 / 870,997, filed August 28, 2013, the contents of which are hereby incorporated by reference in their entirety. [0003] US government rights [0004] This invention was made through work supported by National Institutes of Health grants 1R43CA134071 and 1R43CA137939. The US Government may have rights in this invention. [0005] sequence listing [0006] This application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on June 23, is named "112172-242SequenceListingTEXT" and is 30,360 bytes. technical field [0007] The present invention relates generally to cancer therapy, and more particularly to methods and compositions involving microRNA (miRNA) molecules, such as miR-34, in disease treatment, diagn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q2600/178C12Q1/6886C12Q2600/158C12Q2600/106A61P35/00A61P35/02A61P43/00C12N15/113G01N33/5748G01N33/57496A61K45/06A61K31/7105C12N2310/141C12N2320/30
Inventor 安德里斯·巴德简·赵
Owner MIRNA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap